soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 2025 🔴 Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the soul trial oral semaglutide cardiovascular – Oral Semaglutide's Impact on Cardiovascular

Obes Surg 32(4):10051015 Gorgojo-Martnez JJ, Feo-Ortega G, Serrano-Moreno C (2016) Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery

The active ingredient is the same, so the transition is generally straightforward from a pharmacological standpoint

But then something unexpected took place

The company also sent a comment to the FDA on Friday stating that the requested changes to the label are unsupported by the scientific evidence and legally and procedurally improper. The current warning label on acetaminophen reads if pregnant or breastfeeding, ask a health professional before use. Kenvue stated that this warning is the most conservative and appropriate warning. In its comment, the company urged the FDA not to accept the label changes